Skip to content.

Spotlight

Featured

Perspectives
Why we invested in Infact
1 / 10
Read more
Perspectives
Why we invested in trumpet
2 / 10
Read more
Perspectives
Why we invested in Instinct
3 / 10
Read more
Perspectives
Why we invested in Treefera
4 / 10
Read more
Perspectives
Why we invested in Oriole Networks
5 / 10
Read more
Perspectives
Why we invested in Gridcog
6 / 10
Read more
Perspectives
Why we invested in OpenDialog
7 / 10
Read more
Perspectives
Why we invested in kennek?
8 / 10
Read more
Perspectives
Why we invested in tem.?
9 / 10
Read more
Perspectives
Why we invested in Ramp?
10 / 10
Read more

Perspectives
Simon Goldman on transforming hard science into global impact – Podcast

Simon Goldman on transforming hard science into global impact

Read the article >
News

EpilepsyGTx announces a $10m seed round to treat focal refractory epilepsy

Read the article >
Web

Ed Lascelles, Partner, speaks with Forbes on the launch of the new Radia 2024 programme

Not Enough Women Are Pitching To VCs: Will An Accelerator Help?

Read the article >
Perspectives
ASGCT 2024 highlights: new modalities and economic realities

ASGCT 2024 highlights: new modalities and economic realities

Read the article >
Founder stories

From academia to entrepreneurship with biotech pioneer Prof. Amit Nathwani

Read the article >
Events

HTBC TechBio Session 2

London

Read the article >
Events

HTBC TechBio

HSBC Innovation Banking, London

Read the article >
Web

Universities & pharma companies need each other to create world-changing medicines

Simon Goldman highlights the need of closer partnerships between pharma and universitites on Pharmaforum

Read the article >
News

AstronauTx closes a £48 million Series A to treat Alzheimer’s disease

Read the article >
News

Tenpoint Therapeutics launches with $70 million Series A

Read the article >
Web

Bloomsbury GTx announces publication of article highlighting preclinical data from BGT-NPC programme.

A potential new brain-targeted therapeutic for the treatment of Niemann-Pick Type C Disease (NPC).

Read the article >
Web

Quell Therapeutics signs a $2bn plus deal with AstraZeneca | FT

UCLTF cell therapy startup Quell Therapeutics signs a $2bn plus deal with AstraZeneca | FT

Read the article >